Expression of ILT2, HLA-G, and IL-10 in primary cutaneous cytotoxic lymphomas
Case no. . | Age, y/sex . | TCR gene rearrangement . | Disease stage . | Immunophenotype . | IL T2*(F278) . | HLA-G*(4H84) . | IL-10* . |
|---|---|---|---|---|---|---|---|
| 1 | 39/F† | Vγ1-8, VJ1/2 | IVb | TIA1+perforin+GrB+CD4+CD43+CD56+ | + | + | + |
| 2 | 73/M | Positive‡ | IIb | TIA1+perforin+GrB+CD4+CD43+CD56+ | + | - | - |
| 3 | 52/F† | Positive‡ | IIb | TIA1+perforin+GrB+CD4+CD43+CD56+ | + | + | + |
| 4 | 69/F | Vγ1-8 | Ib | TIA1+perforin-GrB+CD3+CD8+CD43+ | + | + | + |
| 5 | 39/M | Positive‡ | Ib | TIA1+perforin+GrB-CD2+CD3+CD8+ CD43+ | + | + | + |
| 6 | 45/M | Vγ1-8 | Ib | TIA1+perforin+GrB+CD2+CD3+CD8+ CD43+ | + | + | + |
| 7 | 48/M | Vγ1-8 and JP1 | Ia | TIA1+perforin-GrB+CD3+CD8+CD43+ | + | + | + |
Case no. . | Age, y/sex . | TCR gene rearrangement . | Disease stage . | Immunophenotype . | IL T2*(F278) . | HLA-G*(4H84) . | IL-10* . |
|---|---|---|---|---|---|---|---|
| 1 | 39/F† | Vγ1-8, VJ1/2 | IVb | TIA1+perforin+GrB+CD4+CD43+CD56+ | + | + | + |
| 2 | 73/M | Positive‡ | IIb | TIA1+perforin+GrB+CD4+CD43+CD56+ | + | - | - |
| 3 | 52/F† | Positive‡ | IIb | TIA1+perforin+GrB+CD4+CD43+CD56+ | + | + | + |
| 4 | 69/F | Vγ1-8 | Ib | TIA1+perforin-GrB+CD3+CD8+CD43+ | + | + | + |
| 5 | 39/M | Positive‡ | Ib | TIA1+perforin+GrB-CD2+CD3+CD8+ CD43+ | + | + | + |
| 6 | 45/M | Vγ1-8 | Ib | TIA1+perforin+GrB+CD2+CD3+CD8+ CD43+ | + | + | + |
| 7 | 48/M | Vγ1-8 and JP1 | Ia | TIA1+perforin-GrB+CD3+CD8+CD43+ | + | + | + |